Clinical Trials Logo

Enteropathic Arthritis clinical trials

View clinical trials related to Enteropathic Arthritis.

Filter by:
  • None
  • Page 1

NCT ID: NCT04751396 Recruiting - Clinical trials for Rheumatoid Arthritis

Testing of an Educational Tool for Patients With Melanoma and Pre-Existing Autoimmune Disease Who Are Candidates for Immune Checkpoint Inhibitors

Start date: April 20, 2022
Phase:
Study type: Observational

This study learn how easily patients can use an educational tool that will be created for patients with melanoma and pre-existing autoimmune diseases who receive or will receive immune checkpoint inhibitor drugs. Patients will be asked their opinions about the design, accessibility, and content of the tool. Researchers will use the information collected to improve the educational materials that will help patients make future decisions about their treatment.

NCT ID: NCT02538757 Active, not recruiting - Clinical trials for Rheumatoid Arthritis

Safety and Effectiveness Study of the Live Zoster Vaccine in Anti-Tumor Necrosis Factor (TNF) Users (VERVE)

VERVE
Start date: October 2013
Phase: Phase 2
Study type: Interventional

The VaricElla zosteR VaccinE (VERVE) trial evaluates the safety and effectiveness of the herpes zoster (shingles) vaccine, Zostavax, in arthritis patients over 50 years old who are using anti-TNF therapy and who have not previously received the vaccine. This pilot study of 125 patients will serve as a backdrop for the larger study that is currently recruiting NCT02538341.

NCT ID: NCT02538341 Completed - Clinical trials for Rheumatoid Arthritis

Safety and Effectiveness of Live Zoster Vaccine in Anti-Tumor Necrosis Factor (TNF) Users (VERVE Trial)

Start date: May 2016
Phase: Phase 2
Study type: Interventional

The VaricElla zosteR VaccinE (VERVE) trial evaluates the safety and effectiveness of the Herpes zoster (HZ) vaccine for shingles, Zostavax, in patients over 50 years old with arthritis and other diseases who are using anti-tumor necrosis factor (TNF) therapy and who have not previously received the vaccine.